Stocktoria
Esperion Therapeutics, Inc. ESPR
Esperion Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $403.1M | $332.3M | $116.3M | $75.5M | $78.4M | $227.5M | $148.4M | $0 | — | — |
| SG&A expense | $165.8M | $163.1M | $142.5M | $109.1M | $185.0M | $199.6M | $65.9M | $33.1M | — | — |
| Operating income | $60.3M | $54.4M | -$155.6M | -$179.5M | -$226.7M | -$121.4M | -$93.1M | -$204.6M | -$169.0M | -$76.2M |
| Interest expense | — | — | $59.0M | $56.8M | $46.4M | $22.7M | $8.1M | $28,000 | $198,000 | $376,000 |
| Income tax | $1.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$22.7M | -$51.7M | -$209.2M | -$233.7M | -$269.1M | -$143.6M | -$97.2M | -$201.8M | -$167.0M | -$75.0M |
| EPS (diluted) | $-0.11 | $-0.28 | $-2.03 | $-3.52 | $-9.31 | $-5.23 | $-3.59 | — | — | — |
| Operating cash flow | -$13.1M | -$23.7M | -$135.5M | -$174.8M | -$263.8M | -$85.2M | -$70.3M | -$148.6M | -$131.3M | -$47.7M |
| Free cash flow | -$13.1M | -$24.0M | -$135.5M | -$174.8M | -$263.8M | -$86.0M | -$71.3M | -$148.8M | -$131.3M | -$47.8M |
| Cash & equivalents | $167.9M | $144.8M | $82.2M | $124.8M | $208.9M | $305.0M | $166.1M | $37.0M | $34.5M | $38.2M |
| Inventory | $105.1M | $94.5M | $65.6M | $35.2M | $34.4M | $16.1M | $0 | — | — | — |
| Total assets | $465.9M | $343.8M | $205.8M | $247.9M | $381.6M | $353.3M | $214.4M | $143.5M | $277.8M | $245.2M |
| Total liabilities | $767.9M | $732.5M | $660.8M | $571.7M | $578.5M | $449.4M | $194.5M | $64.3M | $33.1M | $16.6M |
| Shareholders' equity | -$302.0M | -$388.7M | -$455.0M | -$323.8M | -$196.9M | -$96.1M | $19.9M | $79.1M | $244.7M | $228.6M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +21.3% | +185.7% | +54.1% | -3.8% | -65.5% | +53.4% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.